AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00796575
Drug: placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablets matching active
Trial: NCT00796575
Drug: CS-8080
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-8080 5 mg tablets, 2 tablets administered 1 times per day
Trial: NCT00796575
Drug: CS-8080
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-8080 5 mg tablets, 4 tablets administered 1 times per day
Trial: NCT00389285
Drug: rIL-21 only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: rIL-21, IV, Day 1-5 and 15-19 of each 6-week treatment course
Trial: NCT02735707
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 80mg administered once daily via enteral route, while the patient remains in hospital up to 28 days after randomisation~Note: this intervention is now closed.
Trial: NCT02735707
Drug: Angiotensin converting enzyme inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Site-preferred ACEi agent administered as directed by the treating clinician for 10 days or until hospital discharge, whichever occurs first.~Note: this intervention is now closed.
Trial: NCT02735707
Drug: ARB + DMX-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Site-preferred ARB agent administered in combination with DMX-200 for 10 days or until hospital discharge, whichever occurs first.~ARB administered as directed by the treating clinician. DMX-200 administered enterally at a dose of 120mg twice daily.~Note: this intervention is now closed.
Trial: NCT02735707
Drug: Cysteamine
RxNorm normalized name: Cysteamine
DrugBank: Cysteamine (DB00847)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cysteamine administered every 8 hours at a dose of 5 mg/kg estimated or measured body weight (maximum dose of 500mg), for ten days or until ICU discharge, whichever occurs first.~Note: this intervention is now closed.
Trial: NCT00071188
Drug: ZD6474
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02614131
Drug: Placebo SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT02614131
Drug: Placebo IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT00296127
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01238094
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: simvastatin 40 mg qd daily until disease progression
Trial: NCT02473458
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05341102
Drug: LY3556050
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05341102
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT00543920
Drug: MK0777
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01923935
Drug: BUSULFEX®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUSULFEX® 3.2 mg/kg/day iv once daily over 3 hours (day-6\~day-4)
Trial: NCT01923935
Drug: Alkeran®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alkeran® 70 mg/m2/day iv once daily over 30 minutes (day-3\~day-2)
Trial: NCT03853525
Drug: BAY207543 (Bepanthol, Bepantol® Derma Spray)
RxNorm normalized name: Derma Gran Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Product is applied to one side of the inguinal region.
Trial: NCT02477280
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medikinet
Trial: NCT01090310
Drug: AIN457
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIN457 150 mg powder for solution was provided in glass vials each containing 150 mg AIN457 as a lyophilized cake
Trial: NCT00445198
Drug: ABT-263
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1 dosing under two different schedules: 14 days on drug, 7 days off or continuous dosing.~- 50 patients with SCLC and non-hematologic malignancies. Enrollment is closed in this arm of the study.~Phase 2a dosing under two different schedules: 14 days on drug, 7 days off or continuous dosing.~- 40 patients with SCLC
Trial: NCT02893618
Drug: Diazoxide choline controlled-release tablet
RxNorm normalized name: diazoxide Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD tablet formulation of choline salt of diazoxide
Trial: NCT03315611
Drug: 'Eucerin AtopiControl Lotion' (for the body)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with Eucerin AtopiControl Lotion
Trial: NCT01945086
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive SC injections of placebo at Week 0 and Week 4.
Trial: NCT00772005
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01606202
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contained peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl. The maximum permitted dose of study medication was eight actuations in any three-hour period, and 48 actuations in any 24 hour period.
Trial: NCT01481272
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 12mg, it, on day 5 of each 21 days cycle, maximum 6 cycles
Trial: NCT01481272
Drug: Leukovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15mg, po 24 hours after methotrexate it
Trial: NCT00212290
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02760056
Drug: Liothyronine sodium
RxNorm normalized name: Liothyronine Sodium
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be divided into 4 groups of progressively escalating doses. Each group will have 6 subjects 4 will receive the active treatment and 2 will receive the placebo. The first group will receive 25 mcg twice daily for one week. The second group will receive 37.5 mcg twice daily for one week. The third group will receive 50 mcg twice daily for one week. The forth group will receive 75 mcg twice daily for one week.
Trial: NCT02760056
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will receive a matching placebo to take twice daily for one week.
Trial: NCT00762554
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epidural fentanyl infusion started after spinal bupivacaine used for the cesarean section.
Trial: NCT01160484
Drug: DVD-R
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg dexamethasone will be administered IV on Days 1, 4, 8, and 11 of each cycle. 1.0 mg/m2 Bortezomib will be administered IV over 3 to 5 seconds followed by a standard saline flush, on Days 1, 4, 8, and 11 immediately following the dexamethasone infusion. 4.0 mg/m2 PLD will be given as a 90 minute infusion on Day 1 of Cycle 1 and subsequent doses may be administered over 30 to 60 minutes on Days 4, 8 and 11 of Cycle 1 and on Days 1, 4, 8, and 11 of each subsequent cycle, following the bortezomib administration. 10 mg/day lenalidomide will be administered PO on days 1-14 of a 28-day treatment cycle, followed by a 14-day rest period, following the PLD administration.
Trial: NCT03161652
Drug: DME lactose pill
RxNorm normalized name: lactose Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with DME will take placebo orally 3 times a day (TID) for 8 weeks.The placebo is taken on top of standard therapy for diabetes and blood pressure control.
Trial: NCT00719914
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-coronary injection, weight based, of normal saline.
Trial: NCT03161652
Drug: DR lactose pill
RxNorm normalized name: lactose Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with non-proliferative DR will take a lactose pill (placebo) orally TID for 8 weeks. The placebo is taken on top of standard therapy for diabetes and blood pressure control.
Trial: NCT03161652
Drug: DR vitrectomy lactose pill
RxNorm normalized name: lactose Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with proliferative DR (undergoing medically prescribed vitrectomy 7 days after starting the study medication) will have to take a lactose pill (placebo) orally TID for one week. The last placebo pill will be taken on the morning of the day vitrectomy is performed. The placebo is taken on top of standard therapy for diabetes and blood pressure control.
Trial: NCT03161652
Drug: DME plus ranibizumab lactose pill
RxNorm normalized name: lactose Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with DME with conventional intravitreal antiangiogenic therapy with ranibizumab (0.5 mg every 4 weeks for 12 weeks) will take a lactose pill (placebo) orally TID for 24 weeks. The placebo is taken on top of standard therapy for diabetes and blood pressure control.
Trial: NCT01561599
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily intravenous administration for four (4) days. The volume of normal saline will vary by estimated weight.
Trial: NCT04560049
Drug: Phenol
RxNorm normalized name: Phenol
DrugBank: Phenol (DB03255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: phenolisation of sinus tract
Trial: NCT02033200
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03596697
Drug: CRV431
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single or multiple dose(s) of CRV431
Trial: NCT03596697
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Placebo dose
Trial: NCT03578146
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03066219
Drug: BRM421
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A topical solution of BRIM421 ophthalmic drops
Trial: NCT03066219
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vehicle ophthalmic drops
Trial: NCT02150070
Drug: ASP2408
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) infusion and subcutaneous (SC) injection
Trial: NCT02150070
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) infusion and Subcutaneous (SC) injection
Trial: NCT01362309
Drug: d-cycloserine.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg administered on two occasions.
Trial: NCT02880293
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: cyclophosphamide (50 mg/kg IV on day +3 and +4)
Trial: NCT02994602
Drug: Nestorone + Testosterone Combination Gel
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The combined gel is a transdermal treatment that will be applied as three single applications to a male subject's arms and shoulders on three different treatment days. The formulation will be a hydro alcoholic gel containing about 1.43% T (14.3 mg T/g gel). About 9 to 14% of the steroid (T or NES) in the gel applied is available to the body. The amount of gel to be applied each application will be approximately 5 mL in volume. The gel application volume will contain 62.5 mg of T that will deliver approximately 6 mg T to the body per day (Swerdloff et al., 2000; Wang et al., 2000). This gel volume will also contain 8.3 mg of NES that will deliver about 0.8 mg of NES to the body per day (NES 8 mg/d + T 60 mg/d (NES8/T60) gel).
Trial: NCT02753205
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infusion of normal saline
Trial: NCT04251962
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epidural solution containing fentanyl 3 mcg/ml (in addition to bupivacaine) in normal saline
Trial: NCT01913158
Drug: Anucort-HC, 25 Mg Rectal Suppository
RxNorm normalized name: Anucort-HC, 25 mg rectal suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone acetate suppositories
Trial: NCT00944658
Drug: Placebo (sugar pill)
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice a day
Trial: NCT01785849
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously (IV) three times per week.
Trial: NCT00004036
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01439399
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control group (C) received an equal volume of saline 0.9 % during 48 h.
Trial: NCT01633359
Drug: Intensive statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the Intensive Atorvastatin protocol indicates that once 80mg Atorvastatin will be administrated before CAG, and then will be followed with 20mg Atorvastatin daily during the entire study period.
Trial: NCT02561741
Drug: COV155
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COV155 tablets
Trial: NCT04214093
Drug: AZD0466
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Arm A, AZD0466 will initially be administered IV over one hour, once weekly to the first cohort of patients. Subsequent cohorts of patients within Arm A are planned to receive sequentially higher doses.~In Arm B, intrapatient dose ramp-ups will involve beginning at a specified starting dose and weekly increasing the dose to a maximum target dose for the cohort.
Trial: NCT01698567
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (normal saline) after induction of anesthesia and before commencement of bypass. ATIII will be dosed using the formula recommended by the manufacturer: (goal activity - baseline activity) x weight (kg) x .714 (Assume: start with 35% activity \[7\], goal 120% activity\[18\], so dose = 120-35 x wt (kg) x .714, e.g. 5 kg infant: 85 x 5 x .714 = 303 units)
Trial: NCT02233075
Drug: REP 2139-Ca + Pegasys (TM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 weeks of REP 2139-Ca (500mg QW IV) followed by: 15 weeks of REP 2139-Ca (250mg QW IV) + Pegasys(TM) (180 ug QW SC) followed by: 33 weeks of Pegasys(TM) (180 ug QW SC)
Trial: NCT00965471
Drug: cipher prescription 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug granules include ginseng,RADIX NOTOGINSENG,prepared RHIZOMA PINELLIAE with alumen radix glyrrhigae calcaren once daily for 180 days
Trial: NCT03871959
Drug: DEBIO1143
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 escalating dose level (100 mg, 150 mg, 200 mg) of Debio 1143 administered daily for 14 days over a 21-day cycle period.
Trial: NCT02722161
Drug: [14C]BI 1482694
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00881907
Drug: Triple Antibiotic Paste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ciprofloxacin, metronidazole \& minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.
Trial: NCT02709265
Drug: amikacin/fosfomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single aerosolized dose
Trial: NCT01581333
Drug: Empirical antimicrobial treatment discontinuation
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical antimicrobial treatment discontinuation will occur when the patient is: Afebrile, with resolution of signs, symptoms and test abnormalities secondary to complementary source of infection and with normalization of vital signs for ≥ 72 h.
Trial: NCT01581333
Drug: Standard empirical antimicrobial treatment discontinuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The empirical antimicrobial treatment discontinuation will occur when the patient is:~The neutrophil count is above 500 million per mm3.
Trial: NCT03583905
Drug: Placebo of CKD-330
RxNorm normalized name: placebo 330 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of CKD-330 Tab.
Trial: NCT03583905
Drug: D086
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D086 Tab.
Trial: NCT03583905
Drug: Placebo of D086
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of D086 Tab.
Trial: NCT03583905
Drug: Placebo of D723
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of D723 Tab.
Trial: NCT00957905
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00957905
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03684772
Drug: ICVT Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin and Furosemide (0.125%)
Trial: NCT02847338
Drug: Amiloride
RxNorm normalized name: Amiloride
DrugBank: Amiloride (DB00594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amiloride 10mg will be one of the treatments in which patients will receive on the dual therapy arm.
Trial: NCT03161509
Drug: Antiepileptic (either carbamazepine, lamotrigine, phenytoin or valproic acid)
RxNorm normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of antiepileptic drug (either carbamazepine, lamotrigine, phenytoin or valproic acid) for which the participant is taking chronically in stable dose
Trial: NCT00553852
Drug: Recombinant GH Saizen (Merck-Serono)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment will start at the initial dose 0.15-0.30 mg/day; dose adjustment will be performed according to IGF-I levels. The duration of medical treatment is 6 months.
Trial: NCT02315872
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections twice weekly for 28 weeks.
Trial: NCT00600405
Drug: Standard therapy with ibuprofen and oxycodone.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone: 5mg, one to two tablets every four to six hours as needed for pain. Ibuprofen: 800 mg, one three times a day with food as needed for pain.
Trial: NCT02642640
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00005867
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00005867
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00005867
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01718223
Drug: photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undergo interstitial photodynamic therapy using temoporfin
Trial: NCT02125409
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One tablet of Adiro 100 mg will be administered daily for 7 days.
Trial: NCT02988232
Drug: Sogyeonghwalhyeol-tang
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: herbal extract
Trial: NCT02988232
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: extract powder with same appearance, odor and color as SGHH
Trial: NCT00430586
Drug: Botulinum neurotoxin type A, free of complexing proteins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single treatment with 10, 20 or 30 Units of NT 201 given as intramuscular treatment injections of equal amount to 5 sites on Day 0. The same volume of reconstituted study medication (0.6 mL per subject) was administered irrespective of the treatment group. The total dose volume was administered in equal aliquots to the 5 injection sites. Thus, each of the 5 injection sites was injected with 0.12 mL study medication per injection site.
Trial: NCT00430586
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single treatment with Placebo given as intramuscular treatment injections of equal amount to 5 sites on Day 0. A volume of reconstituted 0.6 mL per subject was administered. The total dose volume was administered in equal aliquots to the 5 injection sites. Thus, each of the 5 injection sites was injected with 0.12 mL Placebo per injection site.
Trial: NCT02598011
Drug: Toca FC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toca FC is an extended-release formulation of flucytosine. Toca FC is supplied as 500 mg white, oblong tablets with TOCA FC embossed on one side and 500 embossed on the other side
Trial: NCT00335959
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 850 mg/m2/dose PO q 12 hours Days 1-14 and 22-35. 650 mg/m2/dose PO q 12 hours Days 43-77.
Trial: NCT02539134
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-935 placebo-matching oral solution
Trial: NCT06037577
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator
Trial: NCT00862459
Drug: OptiMARK~0.1 mmol/kg BW
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant received one dose of 0.1 mmol/kg BW of OptiMARK. OptiMARK was administered via a power injector at a rate of 2 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
Trial: NCT01921738
Drug: 1% Azithromycin gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received mechanical periodontal therapy, oral hygiene instructions and placement of the in-situ gel (0.2 ml 1% Azithromycin) into the periodontal pockets in single rooted teeth; twice with an interval of 20 minutes.